Search clinical trials for: ciclesonide nasal aerosol

Total 2716 results

Sunovion

Completed

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

Seasonal Allergic Rhinitis

United States
Sunovion

Completed

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).

Perennial Allergic Rhinitis | PAR

United States
Sunovion

Completed

A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)

Perennial Allergic Rhinitis

United States
Sunovion

Completed

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

Perennial Allergic Rhinitis

United States
Sunovion

Completed

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

Perennial Allergic Rhinitis | PAR

United States
Sunovion

Completed

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

Perennial Allergic Rhinitis

United States
Sunovion

Completed

A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler

Allergic Rhinitis (AR)

United Kingdom
Ola Blennow, MD, PhD
Karolinska University Hospital; Danderyd Hospital; Centrallasarettet Västerås

Active, not recruiting

Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) (HALT)

Pneumonia, Viral | Covid-19 | Sars-CoV2

Sweden
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol

Allergic Rhinitis
AstraZeneca

Completed

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

Rhinitis, Allergic, Perennial | Hay Fever

United States
AstraZeneca

Completed

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

Seasonal Allergic Rhinitis | Hay Fever

United States
AstraZeneca

Completed

A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)

Rhinitis, Allergic, Seasonal | Hay Fever

Canada
Apotex Inc.

Completed

A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

Rhinitis, Allergic, Perennial

United States
McGill University Health Centre/Research Institute...

Terminated

Inhaled Ciclesonide for Outpatients With COVID19 (CONTAIN)

COVID 19

Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

Seasonal Allergic Rhinitis | SAR

United States
University of Chicago
Sunovion

Withdrawn

A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray

Allergic Rhinitis

United States
Hamilton Health Sciences Corporation
Takeda; Kolding Sygehus

Completed

Effect of Ciclesonide on Exercise Induced Bronchoconstriction

Asthma

Canada
Universiti Kebangsaan Malaysia Medical Centre

Completed

Impact of Covid-19 Aerosol Box On Intubation Success Rate

Intubation; Difficult or Failed

Malaysia
LEO Pharma

Completed

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Psoriasis Vulgaris

United States, Canada, Germany, United Kingdom, France, Poland
AstraZeneca

Completed

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

Rhinitis, Allergic, Perennial

United States
Sunovion

Completed

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

Seasonal Allergic Rhinitis

United States
Boehringer Ingelheim

Terminated

Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)

Pulmonary Disease, Chronic Obstructive
The First Affiliated Hospital of Soochow University

Recruiting

The Effect of Precise Aerosol Inhalation Nursing on Sputum Excretion in Elderly Patients With Lung Surgery

Inhalation

China
Sunovion

Completed

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United States
University of Pennsylvania
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Acute Effects of E-Cigarette Aerosol Inhalation

Endothelial Dysfunction | Biochemical Markers

United States
Sunovion

Completed

A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Allergic Rhinitis | Perennial Allergic Rhinitis

United States
Massachusetts General Hospital

Recruiting

Quantifying Viral Load in Respiratory Particles That Are Generated by Children and Adults With COVID-19 Infection

COVID-19

United States
University of Malaya

Unknown

Taiwan "Aerosol Box" Versus UMMC "Intubation Box"

COVID-19 | Airway

Malaysia
West Penn Allegheny Health System

Completed

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

Asthma | Allergic Rhinitis

United States
Centre Hospitalier Universitaire de Nice

Recruiting

Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx) (MiOx)

Migraine

France
Bayer

Completed

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer

Breast Neoplasms | Breast Cancer, Metastatic

France, Germany, Spain, Austria, Belgium, Slovenia, Poland, Bulgaria, United Kingdom, Italy
Handok Inc.
Takeda

Completed

Omnaris Versus Levocetirizine Phase 4 Study

Allergic Rhinitis

Korea, Republic of
Allergy & Asthma Medical Group & Research Center

Completed

Evaluation of Traditional Paper Symptom Diary vs. the VOCEL Mobile Diary

Asthma

United States
Derince Training and Research Hospital

Completed

Effect of Using Barrier Devices for Intubation in COVID-19 Patients

COVID-19 | Intubation, Intratracheal

Turkey
Prof. Aviram Nissan

Not yet recruiting

Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial

Metastatic Colorectal Cancer | Peritoneal Carcinomatosis | Colon Adenocarcinoma
Istituto Ortopedico Rizzoli

Completed

Effect of Sulfur Thermal Water on Circulating H2S Levels and Markers of Bone Metabolism in Osteopenic Subjects. (FORST3)

Osteoporosis | Hydrogen Sulfide

Italy
Sanofi
Takeda

Completed

Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma

Asthma
University of Oxford
University of Birmingham

Terminated

MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection

Tuberculosis

United Kingdom
Sanofi

Completed

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

Asthma

United States
Sanofi

Completed

Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

Asthma

United States, Brazil, Poland, Russian Federation, Estonia, Mexico, Israel, Chile, Latvia, Puerto Rico, Costa Rica
Mayo Clinic

Withdrawn

Safety Study of Inhaled Saline in Acute Lung Injury

Pulmonary Edema
Lawson Health Research Institute

Terminated

Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19

COVID-19

Canada
Rush University Medical Center

Terminated

Humidity Therapy for Spontaneously Breathing Tracheostomy Patients

Respiratory Failure

United States
AstraZeneca

Completed

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

Rhinitis, Allergic, Seasonal

United States
AstraZeneca

Completed

Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia

Seasonal Allergic Rhinitis

Russian Federation
Sunovion

Completed

Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray

Perennial Allergic Rhinitis

United States
LEO Pharma

Completed

A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) (LP0113-1123)

Skin and Connective Tissue Diseases

France
University of Roma La Sapienza
Queen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention Srl

Completed

Sulfureous Water Therapy in Viral Respiratory Diseases (STWandRVD)

Post Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 Syndrome

Italy
Sunovion

Completed

A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Perennial Allergic Rhinitis

United States

3

Subscribe